We are live on ! Find out more
CRMD icon

CorMedix
CRMD

11 hedge funds and large institutions have $3.96M invested in CorMedix in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

5% more capital invested

Capital invested by funds: $3.78M → $3.96M (+$182K)

0.02% more ownership

Funds ownership: 1.9% → 1.91% (+0.02%)

8% less funds holding

Funds holding: 12 → 11 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
11
Holders Change
-1
Holders Change %
-8.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$21.9K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$17.8K
3
Goldman Sachs
Goldman Sachs
New York
+$1.7K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$4.76K
2
GSC
Ground Swell Capital
South Carolina
-$1K
3
Millennium Management
Millennium Management
New York
-$191

CRMD Hedge Fund Activity: Q3 2014 in Review

11 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2014, worth a combined $3.96M — up 4.8% from $3.78M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CRMD and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $21.9K. The largest seller was Citigroup, cutting an estimated $4.76K.

  • 11 institutional investors held CorMedix (CRMD) as of Q3 2014, down from 12 in Q2 2014.
  • Funds reported $3.96M of CorMedix stock for Q3 2014, up 4.8% quarter-over-quarter.
  • 0 funds opened new CorMedix positions in Q3 2014 and 1 closed out, a net change of -1 holder.
  • The largest CorMedix buyer in Q3 2014 was Vanguard Group, an estimated $21.9K added.
  • The largest CorMedix seller in Q3 2014 was Citigroup, an estimated $4.76K sold.

Based on aggregated 13F filings for Q3 2014.